Related Experiment Videos
Recent advances in the treatment of bronchiolitis and laryngitis
1Research Institute, Children's Hospital of Eastern Ontario, Ottawa, Canada.
Insights
Pharmacologic agents improve outcomes for children with croup and bronchiolitis. Nebulized epinephrine benefits bronchiolitis patients, while budesonide and dexamethasone aid croup management, potentially reducing hospital admissions.
Area of Science:
- Pediatric respiratory illnesses
- Pharmacologic interventions
- Evidence-based medicine
Background:
- Croup and bronchiolitis are common childhood respiratory conditions.
- Advances in pharmacologic treatments have improved patient outcomes.
- Effective interventions can reduce healthcare costs by lowering hospital admission rates.
Purpose of the Study:
- To review the current evidence on pharmacologic treatments for croup and bronchiolitis in children.
- To evaluate the efficacy of specific agents in improving clinical outcomes and reducing hospitalizations.
- To provide guidance on the appropriate use of medications for these conditions.
Main Methods:
- Systematic review of existing literature on pharmacologic treatments for croup and bronchiolitis.
- Analysis of clinical trial data regarding efficacy, admission rates, and hospitalization duration.
- Evaluation of treatment guidelines and expert consensus.
Main Results:
- Nebulized epinephrine shows significant short-term benefits for bronchiolitis, including improved oxygenation and reduced admissions.
- Glucocorticosteroids are not recommended for hospitalized infants with bronchiolitis.
- Nebulized budesonide and oral dexamethasone improve outcomes for outpatient croup, potentially preventing hospitalization.
- Combined nebulized budesonide and oral dexamethasone may offer optimal results for croup.
- Short observation periods in the emergency department may suffice for croup patients treated with epinephrine and glucocorticoids.
Conclusions:
- Pharmacologic agents offer significant benefits for managing croup and bronchiolitis in children.
- Specific treatments like nebulized epinephrine for bronchiolitis and budesonide/dexamethasone for croup can improve clinical scores and reduce hospitalizations.
- Further research is needed to optimize glucocorticoid dosing for inpatient croup and evaluate benefits in very mild cases.
Abstract:
Progress has been made in the treatment for patients with croup and bronchiolitis in the past decade. By intervening with pharmacologic agents, a better outcome has been documented in children with these diseases. A lower probability of hospital admission means that fewer health care dollars need to be expended in this area. The present state of evidence substantiates the following. Bronchiolitis . Nebulized albuterol causes significant short-term improvement in clinical scores in bronchiolitic children, but there is no evidence that it reduces admission rates or decreases length of hospitalization. . Nebulized epinephrine results in significant improvement in clinical scores and airway resistance in children hospitalized with bronchiolitis and in the emergency department causes acute improvement in oxygenation, decreases length of time in the emergency department and admission rate to hospital. . There is no evidence to support the use of dexamethasone or other glucocorticosteroids for infants hospitalized with bronchiolitis. Croup . Nebulized budesonide or oral dexamethasone results in acute clinical improvement in outpatients with mild to moderate croup, reducing the need for hospitalization. . A combination of nebulized budesonide and oral dexamethasone may provide the best clinical outcome, although further evidence is needed to substantiate this . The required dose of oral dexamethasone may range from 0.15 mg/kg to 0.6 mg/kg for best clinical outcome. . Use of racemic epinephrine or L-epinephrine in the emergency department, especially when used concomitantly with glucocorticoids, does not require automatic hospital admission; a 3-hour observation period in the emergency department may suffice. . Use of intramuscular dexamethasone is difficult to justify in patients with croup who are able to ingest oral medications. Future studies need to examine dosing of glucocorticoids for inpatients with croup. In addition, an important question remains as to whether very mild croup patients (those with no evidence of respiratory distress) might benefit from glucocorticoids administered in the physician's office or the emergency department.